Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.

病毒学 不利影响 安慰剂 血清转化 临床试验 效价 随机对照试验 耐受性 佐剂 内科学 免疫系统 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 抗体效价 中和抗体
作者
David Hillus,Tatjana Schwarz,Pinkus Tober-Lau,Kanika Vanshylla,Hana Hastor,Charlotte Thibeault,Stefanie Jentzsch,Elisa T Helbig,Lena J Lippert,Patricia Tscheak,Marie Luisa Schmidt,Johanna Riege,André Solarek,Christof von Kalle,Chantip Dang-Heine,Henning Gruell,Piotr Kopankiewicz,Norbert Suttorp,Christian Drosten,Harald Bias,Joachim Seybold,Florian Klein,Florian Kurth,Victor M. Corman,Leif E. Sander
出处
期刊:The Lancet Respiratory Medicine 卷期号:9 (11): 1255-1265 被引量:68
标识
DOI:10.1016/s2213-2600(21)00357-x
摘要

Summary Background Heterologous vaccine regimens have been widely discussed as a way to mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 vaccines. We aimed to assess the reactogenicity and immunogenicity of heterologous immunisations with ChAdOx1 nCov-19 (AstraZeneca, Cambridge, UK) and BNT162b2 (Pfizer-BioNtech, Mainz, Germany) compared with homologous BNT162b2 and ChAdOx1 nCov-19 immunisation. Methods This is an interim analysis of a prospective observational cohort study enrolling health-care workers in Berlin (Germany) who received either homologous ChAdOx1 nCov-19 or heterologous ChAdOx1 nCov-19–BNT162b2 vaccination with a 10–12-week vaccine interval or homologous BNT162b2 vaccination with a 3-week vaccine interval. We assessed reactogenicity after the first and second vaccination by use of electronic questionnaires on days 1, 3, 5, and 7. Immunogenicity was measured by the presence of SARS-CoV-2-specific antibodies (full spike-IgG, S1-IgG, and RBD-IgG), by an RBD–ACE2 binding inhibition assay (surrogate SARS-CoV-2 virus neutralisation test), a pseudovirus neutralisation assay against two variants of concerns (alpha [B.1.1.7] and beta [B.1.351]), and anti-S1-IgG avidity. T-cell reactivity was measured by IFN-γ release assay. Findings Between Dec 27, 2020, and June 14, 2021, 380 participants were enrolled in the study, with 174 receiving homologous BNT162b2 vaccination, 38 receiving homologous ChAdOx1 nCov-19 vaccination, and 104 receiving ChAdOx1 nCov-19–BNT162b2 vaccination. Systemic symptoms were reported by 103 (65%, 95% CI 57·1–71·8) of 159 recipients of homologous BNT162b2, 14 (39%, 24·8–55·1) of 36 recipients of homologous ChAdOx1 nCov-19, and 51 (49%, 39·6–58·5) of 104 recipients of ChAdOx1 nCov-19–BNT162b2 after the booster immunisation. Median anti-RBD IgG levels 3 weeks after boost immunisation were 5·4 signal to cutoff ratio (S/co; IQR 4·8–5·9) in recipients of homologous BNT162b2, 4·9 S/co (4·3–5·6) in recipients of homologous ChAdOx1 nCov-19, and 5·6 S/co (5·1–6·1) in recipients of ChAdOx1 nCov-19– BNT162b2. Geometric mean of 50% inhibitory dose against alpha and beta variants were highest in recipients of ChAdOx1 nCov-19–BNT162b2 (956·6, 95% CI 835·6–1095, against alpha and 417·1, 349·3–498·2, against beta) compared with those in recipients of homologous ChAdOx1 nCov-19 (212·5, 131·2–344·4, against alpha and 48·5, 28·4–82·8, against beta; both p Interpretation The heterologous ChAdOx1 nCov-19–BNT162b2 immunisation with 10–12-week interval, recommended in Germany, is well tolerated and improves immunogenicity compared with homologous ChAdOx1 nCov-19 vaccination with 10–12-week interval and BNT162b2 vaccination with 3-week interval. Heterologous prime-boost immunisation strategies for COVID-19 might be generally applicable. Funding Forschungsnetzwerk der Universitatsmedizin zu COVID-19, the German Ministry of Education and Research, Zalando SE.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
神锋天下发布了新的文献求助30
刚刚
霸王丸完成签到,获得积分10
1秒前
Hello应助社恐小青年采纳,获得10
1秒前
1秒前
bocai发布了新的文献求助10
1秒前
一直完成签到,获得积分10
2秒前
2秒前
00发布了新的文献求助10
2秒前
852应助略略略采纳,获得10
2秒前
紧张的世德完成签到 ,获得积分10
3秒前
桐桐应助ccyh采纳,获得10
3秒前
4秒前
4秒前
ajing发布了新的文献求助10
5秒前
情怀应助我不李解采纳,获得10
5秒前
CLY完成签到,获得积分10
6秒前
6秒前
LDG发布了新的文献求助10
6秒前
chang_top应助AZE采纳,获得20
7秒前
量子星尘发布了新的文献求助10
7秒前
lalala发布了新的文献求助10
7秒前
7秒前
含蓄绿兰发布了新的文献求助10
7秒前
SYLH应助gjw采纳,获得10
8秒前
ED发布了新的文献求助200
8秒前
9秒前
情怀应助怕孤单的问雁采纳,获得10
9秒前
9秒前
10秒前
10秒前
鲜于飞薇发布了新的文献求助10
11秒前
FashionBoy应助刘佳敏采纳,获得10
12秒前
SYLH应助gjw采纳,获得10
13秒前
风轻萤发布了新的文献求助10
13秒前
LXL0125完成签到,获得积分10
13秒前
传奇3应助自觉紫安采纳,获得10
14秒前
14秒前
尤幻雪发布了新的文献求助30
14秒前
朴实的悲完成签到,获得积分20
14秒前
笑点低的小天鹅完成签到,获得积分10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971091
求助须知:如何正确求助?哪些是违规求助? 3515797
关于积分的说明 11179488
捐赠科研通 3250872
什么是DOI,文献DOI怎么找? 1795536
邀请新用户注册赠送积分活动 875891
科研通“疑难数据库(出版商)”最低求助积分说明 805207